Quadria Capital led investors are exploring a majority stake acquisition in Samarth Lifesciences, with the deal potentially valuing the company at ₹4,500 crore.
Glimpse:
A consortium led by Quadria Capital is evaluating the acquisition of an 80–85% stake in Samarth Lifesciences, a critical care drug manufacturer. The deal could value the company at around ₹4,500 crore, highlighting strong investor interest in India’s pharmaceutical sector.
Quadria Capital, along with a group of private equity investors, is in advanced discussions to acquire a controlling stake in Samarth Lifesciences, a Mumbai based pharmaceutical company specializing in critical care drugs. The proposed transaction could value the company at approximately ₹4,500 crore, making it a significant deal in India’s healthcare investment landscape.
The consortium is reportedly targeting an 80–85% stake, while the company’s promoters are expected to retain a minority share of around 15–20% after the deal. Investment bank O3 Capital has been engaged to advise on the transaction process.
Founded in 1963, Samarth Lifesciences has built a diversified pharmaceutical portfolio spanning critical care, cardiology, anti-infectives, oncology, urology, and gynaecology segments. The company has demonstrated strong financial performance, reporting steady growth and expanding its presence in both domestic and international markets.
The potential investment comes amid rising interest from global private equity firms in India’s pharmaceutical and healthcare sectors, driven by strong demand, export potential, and supply chain diversification. However, the deal is not without challenges. Valuation differences between promoters and investors have reportedly been a sticking point in previous negotiations, and similar concerns may influence the final outcome.
If finalized, the transaction would provide Samarth Lifesciences with capital to scale operations, expand manufacturing capabilities, and strengthen its global footprint. For Quadria Capital, it would reinforce its strategy of investing in high growth healthcare platforms across Asia.
Overall, the deal reflects a broader trend of increased private equity activity in India’s pharma sector, as investors seek to capitalize on the country’s growing role in global healthcare manufacturing and innovation.
“Investor interest in India’s pharma sector is surging and Samarth Lifesciences is at the center of this high stakes deal.”
By
HB Team
